Bio waiver for lower strength (250mg) Mycophenolate mofetil tablet [Regulatives / Guidelines]

posted by Nidhiya J S – United Arab Emirates, 2019-11-05 06:14  – Posting: # 20749
Views: 2,212

(edited by Nidhiya J S on 2019-11-06 06:08)

Dear All,

Greetings!

Please, I would like to know that, with the In vitro comparative dissolution study report can we waive off BE In vivo study with in vitro comparative dissolution study for the lower strength for Mycophenolate mofetil tablet 250mg or do we require separate BE study for the lower strength.


And also I would like to know that whether similar approach can be taken for all the pro-drug where the metabolite of the drug is pharmacologically active.


Waiting for your valuable comments.

With Regards,

Nidhiya

Complete thread:

Activity
 Admin contact
20,641 posts in 4,327 threads, 1,437 registered users;
online 18 (2 registered, 16 guests [including 10 identified bots]).
Forum time: 12:36 CEST (Europe/Vienna)

I have had my results for a long time:
but I do not yet know how I am to arrive
at them.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5